95576-84-4

Basic information

• Product Name: N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2)
• Synonyms: N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2);1,2-BENZENEDIAMINE, N2-METHYL-4-NITRO-;N2-Methyl-4-nitro-1,2-benzenediaMine;2-AMino-5-(N-MethylaMino)nitrobenzene;N1-methyl-5-nitrobenzene-1,2-diamine;N2-Methyl-4-Nitro-1,2-Benzenediamine(WX690280)
• CAS NO: 95576-84-4
• Molecular Formula: C₇H₉N₃O₂
• Molecular Weight: 167.167
• Product Categories: Aromatics;Amines;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 95576-84-4.mol

Chemical Properties

• Melting Point: 168-170°C
• Boiling Point: 372.0±32.0 °C(Predicted)
• Appearance: /
• Density: 1.358±0.06 g/cm3(Predicted)
• PKA: 3.99±0.26(Predicted)
• CAS DataBase Reference: N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2)(CAS DataBase Reference)
• NIST Chemistry Reference: N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2)(95576-84-4)
• EPA Substance Registry System: N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2)(95576-84-4)

Safety Data

• Hazardous Substances Data: 95576-84-4(Hazardous Substances Data)

Usage

Uses

Used in Textile Industry:
N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2) is used as a dye component for keratin fibers, such as wool and silk, due to its ability to impart color and enhance the appearance of these natural fibers.
Used in Cosmetic Industry:
In the cosmetic industry, N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2) is used as a dye component for hair coloring products, providing a wide range of shades and tones to suit various preferences and styles.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, N'-METHYL-4-NITROPHENYLENEDIAMINE-(1,2) may also have potential applications in the pharmaceutical industry, possibly as an intermediate in the synthesis of certain drugs or as a component in diagnostic reagents, given its chemical properties and reactivity.

Upstream product

• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 74-88-4 methyl iodide 
• 857005-56-2 toluene-4-sulfonic acid-(2-chloro-N-methyl-5-nitro-anilide) 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 101513-60-4 2-chloro-N-methyl-5-nitro-aniline 
• 408509-08-0 toluene-4-sulfonic acid-(2-amino-N-methyl-5-nitro-anilide) 

Downstream Products

• 5381-79-3 1-methyl-6-nitro-1H-benzoimidazole 
• 929193-22-6 ethyl 3-(1-methyl-6-nitro-1H-benzimidazol-2-yl)propanoate 
• 5601-10-5 1-methyl-6-nitro-1H-benzo[d]imidazol-2-amine 
• 25877-35-4 1-methyl-6-nitro-1H-benzo[d][1,2,3]triazole 
• 73778-92-4 5-amino-3-methyl-1H-benzimidazol-2-one hydrochloride 
• 26861-23-4 6-amino-1-methyl-1H-benzotriazole 
• 26947-54-6 5-acetylamino-1-methyl-1H-benzotriazole 
• 26530-93-8 1-methyl-6-amino-1H-benzo[d]imidazole 

Relevant articles and documents

Selective sodium channel regulator as well as preparation and application thereof

The invention provides a compound serving as a selective sodium channel regulator and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the selective sodium channel regulator. The compounds exhibit excellent activity as a regulator of sodium channels.

Discovery of selective fragment-sized immunoproteasome inhibitors

Proteasomes contribute to maintaining protein homeostasis and their inhibition is beneficial in certain types of cancer and in autoimmune diseases. However, the inhibition of the proteasomes in healthy cells leads to unwanted side-effects and significant effort has been made to identify inhibitors specific for the immunoproteasome, especially to treat diseases which manifest increased levels and activity of this proteasome isoform. Here, we report our efforts to discover fragment-sized inhibitors of the human immunoproteasome. The screening of an in-house library of structurally diverse fragments resulted in the identification of benzo[d]oxazole-2(3H)-thiones, benzo[d]thiazole-2(3H)-thiones, benzo[d]imidazole-2(3H)-thiones, and 1-methylbenzo[d]imidazole-2(3H)-thiones (with a general term benzoXazole-2(3H)-thiones) as inhibitors of the chymotrypsin-like (β5i) subunit of the immunoproteasome. A subsequent structure-activity relationship study provided us with an insight regarding growing vectors. Binding to the β5i subunit was shown and selectivity against the β5 subunit of the constitutive proteasome was determined. Thorough characterization of these compounds suggested that they inhibit the immunoproteasome by forming a disulfide bond with the Cys48 available specifically in the β5i active site. To obtain fragments with biologically more tractable covalent interactions, we performed a warhead scan, which yielded benzoXazole-2-carbonitriles as promising starting points for the development of selective immunoproteasome inhibitors with non-peptidic scaffolds.

QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R7, R8, R9, R11, n and p are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modulators that are useful in the treatment of diseases in which the M1 receptor is involved, including Alzheimer's disease, schizophrenia, pain and sleep disorders. The invention also relates to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, and to methods of using the compounds of Formula (I) in the treatment of diseases mediated by the M1 receptor.

BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF IN CANCER THERAPY

The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS

The present invention relates to bendamustine derivatives and related compounds as well as their medical application.

Bendamustine derivatives as anti-proliferative agents

The present invention relates to bendamustine derivatives and related compounds as well as their medical application.

BENDAMUSTINE DERIVATIVES AND RELATED COMPOUNDS, AND MEDICAL USE THEREOF CANCER THERAPY

The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

Synthesis and stability of 5-, 7- and 8-substituted benzo-1,2,3,5-tetrazepin-4-ones

In order to determine the effect of substituents on the stability of benzo-fused 1,2,3,5-tetrazepin-4-ones, 5-, 7- and 8-substituted derivatives (6a-d), and (10) were synthesized. The stability of the tetrazepinones increased with the electron withdrawing character of the substituents at the benzene ring. Bulky groups at the 5 position destabilize the tetrazepinone ring. The unstable tetrazepinones (6b, 10 and 14) decomposed in chloroform at room temperature to benzotriazole derivatives (11, 12 and 15). X-Ray diffraction of nitrobenzotetrazepinone (6d) showed that despite the elctron withdrawing effect of the nitro group para to the triazene chain, N3 exhibited a significant pyramidal character. In 6d, the 1,2,3,5-tetrazepinone cycle has an almost perfect seven-membered ring boat shape.